26.11.2020 • News

Arkema Starts Up Extra China Kynar Capacity

Arkema plans to start up its 50% expansion of Kynar fluoropolymer capacity at Changshu, China, next month. First commercial volumes will be supplied starting January 2021, the French specialty chemicals group said.

The investment in the extra polyvinylidene fluoride (PVDF) output was driven by strongly growing demand for lithium-ion batteries used in electric vehicles and consumer electronic devices, as well as energy storage. Arkema said the global lithium-ion market continues to expand at an accelerating pace and the project further consolidates its world-leading position in PVDF.

“Our unique global Kynar fluoropolymer production footprint enables us to support the growth of our customers with speed and versatility,” said Erwoan Pezron, senior vice president, high performance polymers.

Arkema last invested in additional Kynar capacity in April 2018, when it started up a 20% expansion at its plant in Calvert City, Kentucky, USA.

Author: Elaine Burridge, Freelance Journalist

Arkema will start up its Kynar fluoropolymer expansion in China next month....
Arkema will start up its Kynar fluoropolymer expansion in China next month. First commercial volumes will be supplied starting January 2021. The investment was driven by strongly growing demand for lithium-ion batteries used in electric vehicles and consumer electronic devices. (c) Arkema

Interview

Driving Transformation
Interconnected Global Chemicals Logistics

Driving Transformation

DP World is reshaping global chemical supply chains. Christene Smith of CHEManager interviews Markus Kanis, Global SVP Chemicals, on the company’s roadmap, new technologies, and the evolving demands of global trade.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read